Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
- Digital Object Identifier
- https://doi.org/10.14283/jpad.2022.63
- Open Access
- http://aura.abdn.ac.uk/bitstreams/4b8d981b-d1b0-43ab-bbbc-a90581c02b21/download
- Additional Links
- View publication in Scopus